Genmab A/S, which develops therapies based on fully human antibodies, expects to report revenue of 1 billion Danish Krone (DKK) in 2008. However, it is projecting an operating loss of DKK 900 to 1,000 million and a net loss in the range of DKK 800 to 900 million.
